文献速递慢阻肺

肺弥散功能与静态肺过度充气预测COPD三年死亡风险

Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.
PubMed 文献 · Respirology · 2024-10-24

基于德国COSYCONET队列1364例COPD患者,分析18个月时疾病进展指标与18-54个月死亡率的关联。发现KCO%预计值下降≥7.5%和RV/TLC增加≥2%是最常见的进展指标,分别见于约52%和46%患者,且与中期死亡风险增加相关。这些新标志物无法被基线生物标志物预测。

要点

  • KCO%预计值下降≥7.5%和RV/TLC增加≥2%是18个月时最常见的疾病进展指标。
  • KCO%预计值下降、RV/TLC增加、FEV1下降、SGRQ恶化及急性加重分级2均与18-54个月死亡风险增加相关。
  • IL-6和CRP阈值与中远期疾病指标显著相关,但基线生物标志物无法预测这些进展。

核心结论

  • 在COPD多中心队列中,反映当前疾病活动的新标志物可预测中期死亡率,且无法被基线生物标志物预判。

研究设计与样本

  • 分析德国观察性COSYCONET队列1364例COPD患者数据,采用Cox hazard回归模型评估疾病进展对死亡率的影响,并用逻辑回归和随机森林模型评估生物标志物与进展表型的关联。

主要发现

  • 18-54个月死亡风险增加与KCO%预计值下降(每7.5%增量)、FEV1下降(每20 mL增量)、RV/TLC增加(每2%增量)、SGRQ恶化(≥6分)及18个月时急性加重分级2相关。
  • KCO%预计值下降≥7.5%和RV/TLC增加≥2%分别出现在约52%和约46%的患者中,是最常见的18个月疾病进展指标。
  • IL-6和CRP阈值与中期和长期疾病指标存在显著关联。

临床怎么用

  • 临床随访COPD患者时可关注KCO%预计值和RV/TLC的动态变化,作为疾病进展和死亡风险的补充标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Chronic obstructive pulmonary disease (COPD) exhibits diverse patterns of disease progression, due to underlying disease activity. We hypothesized that changes in static hyperinflation or KCO % predicted would reveal subgroups with disease progression unidentified by preestablished markers (FEV1, SGRQ, exacerbation history) and associated with unique baseline biomarker profiles. We explored 18-month measures of disease progression associated with 18-54-month mortality, including changes in hyperinflation parameters and transfer factor, in a large German COPD cohort. METHODS: Analysing data of 1364 patients from the German observational COSYCONET-cohort, disease progression and improvement patterns were assessed for their impact on mortality via Cox hazard regression models. Association of biomarkers and COPD Assessment test items with phenotypes of disease progression or improvement were evaluated using logistic regression and random forest models. RESULTS: Increased risk of 18-54-month mortality was linked to decrease in KCO % predicted (7.5% increments) and FEV1 (20 mL increments), increase in RV/TLC (2% increments) and SGRQ (≥6 points), and an exacerbation grade of 2 at 18 months. Decrease in KCO % predicted ≥7.5% and an increase of RV/TLC ≥2% were the most frequent measures of 18-month disease progression occurring in ~52% and ~46% of patients, respectively. IL-6 and CRP thresholds exhibited significant associations with medium- and long-term disease measures. CONCLUSION: In a multicentric cohort of COPD, new markers of current disease activity predicted mid-term mortality and could not be anticipated by baseline biomarkers.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Pott, Weckler, Gaffron, et al. Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET. Respirology. 2024. PMID: 39448064. doi:10.1111/resp.14843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。